Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 16/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PRKX | P51817 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652673 | 0.93 | MME (0.42) | MME | |
| SCHEMBL652672 | 0.93 | MME (0.42) | MME | |
| SCHEMBL651065 | 0.91 | AGTR1 (0.39) | MMEAGTR1AGTR2 | |
| SCHEMBL652532 | 0.90 | MME (0.40) | MMEAGTR1CTRB1 | |
| SCHEMBL654141 | 0.88 | MME (0.42) | MMEAGTR1AGTR2 | |
| SCHEMBL652659 | 0.88 | MME (0.43) | MMEAGTR1ROCK2RPS6KA5RPS6KA4 | |
| SCHEMBL651753 | 0.88 | MME (0.40) | MMEAGTR1CTRB1 | |
| SCHEMBL994370 | 0.88 | MME (0.40) | MMEAGTR1CTRB1 | |
| SCHEMBL651920 | 0.87 | MME (0.48) | MMEAGTR1ROCK2RPS6KA5RPS6KA4 | |
| SCHEMBL651498 | 0.85 | MME (0.39) | MMEAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119634-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7956054-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 10/4885AGTR1 1/4885ROCK2 749/4885 |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | MME 13/4885AGTR1 1/4885ROCK2 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.